Literature DB >> 6417069

A 55,000 Mr surface antigen on activated human T lymphocytes defined by a monoclonal antibody.

M E Hemler, B Malissen, N Rebai, A Liabeuf, C Mawas, F M Kourilsky, J L Strominger.   

Abstract

A T cell growth factor-dependent alloreactive human T cell line has been used to generate a monoclonal antibody B1.49.9 that reacts with an antigen present on most if not all mitogen or alloantigen activated T cells but not on resting T cells. The T lymphoblastoid cell line HUT-102 is also strongly reactive with B1.49.9 but all other T and non-T leukemia-lymphoma cell lines tested were negative. The B1.49.9 antigen is a glycoprotein of 55,000 Mr on mitogen or alloantigen activated T cells and 50,000 Mr on the cell line HUT-102. Pulse labeling experiments showed that a 40,000 Mr precursor (at approximately 0.7 h) which does not bind to ricin lectin precedes the appearance of the ricin-binding 55,000 Mr form. Comparisons of the monoclonal antibody anti-Tac, which recognizes the IL-2 receptor, to B1.49.9 suggest that B1.49.9 also recognizes a structure similar or identical to the IL-2 receptor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6417069     DOI: 10.1016/0198-8859(83)90010-1

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  12 in total

1.  Expression of Tac antigen in B cell lymphomas.

Authors:  G Laurent; T Al Saati; D Olive; J C Laurent; P Poncelet; G Delsol
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

2.  Limiting dilution analysis (LDA) of cells responding to recombinant interleukin-2 without previous stimulation: evidence that all responding cells are lymphokine-activated potent effectors.

Authors:  H Vie; M Bonneville; P Sondermeyer; J F Moreau; J P Soulillou
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

3.  A human cytotoxic lymphocyte subdividing the DQ1 antigen.

Authors:  J D Fraser; J L Strominger
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  Dissociation between onset of natural killer E-rosette forming cells and of T3-positive cells following HLA-mismatched T cell depleted bone marrow transplantation.

Authors:  J P De Villartay; F Le Deist; C Griscelli; A Fischer
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

5.  Purification and chemical characterization of the receptor for interleukin 2 from activated human T lymphocytes and from a human T-cell lymphoma cell line.

Authors:  D L Urdal; C J March; S Gillis; A Larsen; S K Dower
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

6.  Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation.

Authors:  M E Hemler; D Glass; J S Coblyn; J G Jacobson
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

7.  Antigenic stimulation regulates the level of expression of interleukin 2 receptor on human T cells.

Authors:  M E Hemler; M B Brenner; J M McLean; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

8.  Interleukin 2-dependent release of interleukin 3 activity by T4+ human T-cell clones.

Authors:  A A Ythier; M Abbud-Filho; J M Williams; R Loertscher; M W Schuster; A Nowill; J A Hansen; D Maltezos; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Autocrine growth stimulation of a human T-cell lymphoma line by interleukin 2.

Authors:  V Duprez; G Lenoir; A Dautry-Varsat
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

10.  Proliferation of thymic stem cells with and without receptors for interleukin 2. Implications for intrathymic antigen recognition.

Authors:  J P Lugo; S N Krishnan; R D Sailor; P Koen; T Malek; E Rothenberg
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.